- Citations, last 5 years
- 0
- Works, last 5 years
- 2
- h-index
- 26
- Scientists listed
- 0
- Grants since 2016
- 16
Grants received
2022–2025 · research · R44
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents
Dennis Liang Fei · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2022–2023 · research · R43
Small Molecule N-myc Degraders as Novel Cancer Therapeutic Agents
Dennis Liang Fei · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2022–2025 · research · R44
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents
Dennis Liang Fei · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Development of Notch1-selective Small Molecule Inhibitor for the Treatment of Cancer
William Russell Guerrant · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Development of Notch1-selective Small Molecule Inhibitor for the Treatment of Cancer
Dennis Liang Fei · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2020–2021 · research · R43
Small Molecule Inhibitors of Notch Activation Complex Kinase (NACK) as Novel Cancer Therapeutic Agents
Dennis Liang Fei · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2018–2019 · research · R43
Development of an Oral WNT inhibitor
Darren Orton · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2018–2021 · research · R44
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)
Darren Orton · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2018–2019 · research · R44
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)
Darren Orton · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2018–2021 · research · R44
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)
Darren Orton · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2018–2019 · research · R43
Development of Notch Pathway Specific Inhibitors as Targeted Therapeutics for Cancer
Darren Orton · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Development of a LRP6 Monoclonal Antibody for Triple Negative Breast Cancer
Darren Orton · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Development of a WNT Inhibitor for Regenerative Healing of Burn Injuries
Marcy Lynn Guerra · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2010–2020 · research · R44
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER
Darren Orton · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2010–2020 · research · R44
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER
Darren Orton · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
2010–2021 · research · R44
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER
Darren Orton · StemSynergy Therapeutics (United States) · funded by National Institutes of Health
